Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€67.75

€67.75

-0.070%
-0.05
-0.070%
€65.00
 
15.07.24 / Tradegate WKN: 663200 / Name: MorphoSys / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

MorphoSys AG Stock

With only a change of -€0.050 (-0.070%) the MorphoSys AG price is nearly unchanged from yesterday.
Our community is currently low on MorphoSys AG with 7 Buy predictions and 11 Sell predictions.
A slightly negative potential of -4.06% at a current price of 67.75 € for MorphoSys AG is the result of a target price of 65 €.
For the coming years our community has positive and negative things to say abot the MorphoSys AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

MorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.

Pros and Cons of MorphoSys AG in the next few years

Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of MorphoSys AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
MorphoSys AG -0.070% 0.000% 2.652% 145.649% 98.680% 18.735% -27.072%
Evotec SE -1.930% -9.434% 5.714% -59.210% -58.427% -75.961% -65.648%
Arrowhead Pharmaceuticals Inc. 0.080% 13.844% 9.603% -14.304% -5.966% -50.486% 7.206%
Ironwood Pharmaceuticals - -1.653% 10.185% -34.615% -41.667% -43.868% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-20

MorphoSys, a company in the Biotechnology & Medical Research industry, seems to have experienced a mixed financial performance in recent years. A quick glance at the financials indicates a trend of fluctuating figures across various metrics. The company's total assets, liabilities, and stockholder's equity have seen considerable shifts over time, ultimately leading to an overall mixed impression of the company's financial status.

*Pros: *

Growth in Total Assets: The company's total assets increased from €1,659,513,020 in 2020 to €2,556,254,216 in 2021, demonstrating a remarkable growth. Although the figures decreased slightly to €2,396,932,263 in 2022, the overall trend points towards a healthy financial condition.

Comments

Buy MorphoSys AG
Show more

Buy MorphoSys AG
Show more

systinvest bought the security MorphoSys AG in his wikifolio Aktienwertselektion mit System.
Show more

News

EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global  Market: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders